Moreover, recent data reported by Shen and colleagues correlate loss-of-function mutations in ARID1A with the efficacy of anti-PD1 therapy, as a result of enhanced intratumoral lymphocyte recruitment and up-regulation of PD-L1 in preclinical models of ovarian cancer [49]. This evidence concerns the gene ARID1A and ovarian carcinoma.